SG Americas Securities LLC Has $243,000 Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

SG Americas Securities LLC grew its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 44.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,036 shares of the company’s stock after acquiring an additional 4,291 shares during the quarter. SG Americas Securities LLC’s holdings in Entrada Therapeutics were worth $243,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of TRDA. Janus Henderson Group PLC boosted its holdings in Entrada Therapeutics by 10.5% in the 3rd quarter. Janus Henderson Group PLC now owns 1,711,459 shares of the company’s stock valued at $27,358,000 after purchasing an additional 161,962 shares during the period. Geode Capital Management LLC boosted its stake in shares of Entrada Therapeutics by 8.8% in the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after buying an additional 46,512 shares during the period. State Street Corp boosted its stake in shares of Entrada Therapeutics by 5.5% in the third quarter. State Street Corp now owns 469,601 shares of the company’s stock valued at $7,504,000 after buying an additional 24,385 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in Entrada Therapeutics by 50.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 201,803 shares of the company’s stock worth $3,225,000 after acquiring an additional 67,559 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Entrada Therapeutics by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 185,984 shares of the company’s stock valued at $2,972,000 after acquiring an additional 23,643 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Entrada Therapeutics

In related news, CFO Kory James Wentworth sold 5,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $20.00, for a total transaction of $100,000.00. Following the sale, the chief financial officer now owns 73,849 shares in the company, valued at $1,476,980. The trade was a 6.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total value of $476,359.95. Following the completion of the transaction, the insider now owns 4,402,849 shares of the company’s stock, valued at $91,447,173.73. This represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,681 shares of company stock valued at $851,199. 7.59% of the stock is currently owned by insiders.

Entrada Therapeutics Stock Down 3.6 %

Shares of TRDA stock opened at $13.48 on Friday. The business has a fifty day simple moving average of $16.41 and a 200 day simple moving average of $16.57. The company has a market cap of $504.42 million, a P/E ratio of 8.48 and a beta of -0.17. Entrada Therapeutics, Inc. has a twelve month low of $11.35 and a twelve month high of $21.79.

Analysts Set New Price Targets

Several research firms have recently issued reports on TRDA. Roth Capital raised Entrada Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm initiated coverage on shares of Entrada Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $29.00 price objective for the company. Oppenheimer raised their target price on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Tuesday.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.